Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | TARDBP | Q13148 | 2/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.81 |
| ▸ | THRB | P10828 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | ACHE | P22303 | 1/20 | 0.81 |
| ▸ | APEX1 | P27695 | 1/20 | 0.81 |
| ▸ | RECQL | P46063 | 1/20 | 0.81 |
| ▸ | BLM | P54132 | 1/20 | 0.81 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.81 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.81 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7908048 | 0.98 | HSD17B10 (0.78) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL22140620 | 0.98 | HSD17B10 (0.78) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL5685853 | 0.95 | HSD17B10 (0.72) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Lipoic Acid, Alpha SCHEMBL51065 | 0.89 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Thioctic Acid SCHEMBL4611014 | 0.89 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Lipoic Acid, Alpha SCHEMBL1981737 | 0.89 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Thioctic Acid SCHEMBL7924 | 0.89 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Lipoic Acid, Alpha SCHEMBL2128472 | 0.89 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL25257437 | 0.88 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL7914749 | 0.88 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SEAGEN INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SEAGEN INC (US) | 2023-06-08 | — | — | US | disclosed |
| CN-110963916-B | Preparation method of 2- (acetoxyethyl) cyclohexanone | 上海现代制药股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-112806502-A | Plant health-care beverage | 郑仙兰 | 2021-05-18 | — | — | CN | disclosed |
| CN-112807324-A | Cactus polysaccharide composition, blood pressure lowering medicine and health food | 郑仙兰 | 2021-05-18 | — | — | CN | disclosed |
| WO-2020132655-A1 | ADCS WITH THIOL MULTIPLEX LINKERS | SEATTLE GENETICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| CN-110963916-A | Preparation method of 2- (acetoxyethyl) cyclohexanone | 上海现代制药股份有限公司 | 2020-04-07 | — | — | CN | disclosed |
| EP-3297626-A1 | OPHTHALMIC COMPOSITION COMPRISING LIPOIC ACID AND A MUCOMIMETIC POLYMER | Ophtalmis Monaco (MC) | 2018-03-28 | — | — | EP | disclosed |
| US-9112160-B2 | Field-effect transistor comprising a leakage-current limiter | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-08-18 | — | — | US | disclosed |
| US-20140183513-A1 | FIELD-EFFECT TRANSISTOR COMPRISING A LEAKAGE-CURRENT LIMITER | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-07-03 | — | — | US | disclosed |
| WO-2010065069-A2 | COMPOSITIONS COMPRISING RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM INHIBITORS AND LIPOIC ACID COMPOUNDS, AND THE USE THEREOF FOR THE TREATMENT OF RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM RELATED DISORDERS | IN VASC THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SSB, UACA, CDA | HSD17B10 2163/4885KMT2A 199/4885TARDBP 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.